Home Trending Stocks Cocrystal Pharma, Inc. (COCP) Stock Skyrocketed Following Promising Updates on Covid-19 Drug...

Cocrystal Pharma, Inc. (COCP) Stock Skyrocketed Following Promising Updates on Covid-19 Drug Development

Cocrystal Pharma, Inc. (COCP) stock prices were up by a monumental 72.58% as of the market closing on may 4th 2021, bringing the price per share up to USD$2.14 at the end of the trading day. Subsequent pre-market fluctuations saw the stock fall by a significant 22.9%, bringing it down to USD$1.65.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Covid-19 Treatment Program

COCP was already in the business of the discovery and development of novel antiviral therapies, designed to target the replication mechanisms of a range of virus types, including coronaviruses. The company recently announced progress in the development of broad-spectrum antiviral drug candidates that target coronaviruses, including SARS-CoV-2, the virus that causes Covid-19. The Covid-19 program was initiated in March of 2020 and has since been expanded with further development and licensing.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

Read More

Success of Treatments in Development

As the global pandemic rages on while the world hurtles towards universal immunizations, COCP is aggressively developing therapies for Covid-19. The company has allocated resources towards developing protease inhibitors for prophylactic and therapeutic use in Covid-19 cases, with the drug candidates bind to an active site of the virus protease that is responsible for Covid-19’s viral replication. Using proprietary high-res x-ray co-crystal structures, the company further confirmed the interaction between the drug candidate and the conserved region of the proteases of various coronaviruses.

Circumventing Issues Posed by Covid-19 Variants

As a result of the drug candidates’ innovate mechanism of action, COCP anticipates the protease inhibitors being developed to be effective against the various strains of SARS-CoV-2 springing up across the world. This is despite variants of Covid-19 possibly being more contagious and immune to existing vaccines and therapies.

Promising Scope of CDI-45205

December 2020 saw the announcement of the selection of CDI-45205 as COCP’s leading coronavirus development candidate, among many, following the acquisition of an exclusive licensing agreement with Kansas State University Research Foundation earlier in 2020. The drug exhibited promising bioavailability in rodent pharmacokinetic studies and showed no signs of cytotoxicity against a number of human cell lines. CDI-45205 also has demonstrably strong synergistic effects with the FDA-approved Covid-19 drug remdesivir.

Expanding Covid-19 Drug Candidates

The company has continued to leverage its expertise in antiviral development to facilitate the launch of a second Covid-19 program. Using proprietary COCP technology and their drug discovery platform, the company is aiming to develop additional antiviral compounds that will aid in the global efforts towards universal immunizations.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

Future Outlook for COCP

With the world hurtling towards a resolution to the global pandemic, COCP is at the forefront of the race to supply nearly every economy in the world with Covid-19 treatments, armed with its recent generation of USD$40 million in capital from a recent underwriting agreement. Current and potential investors are hopeful that the company will be able to leverage its resources to capitalize on an unfortunate opportunity that was already well within its area of expertise, thus ushering in unprecedented increases in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Amarin Corporation plc (NASDAQ: AMRN) stock plunged in the premarket trading session; here’s why

In the premarket trading session, Amarin Corporation plc (AMRN) stock had plunged by -4.56% to $4.4. AMRN stock closed previous session at $4.61 gaining...

Why Second Sight Medical Products, Inc. (EYES) stock is Popping High today?

Second Sight Medical Products, Inc. (EYES) stock announced two-year results of its Orion Study after which the EYES stock price happened to be green...

Luokung Technology Corp. (LKCO) Stock Undergoes Volatility as Appeal Over CCMC Designation is Underway

Luokung Technology Corp. (LKCO) stock prices were down by 6.40% as of the market closing on May 11th, 2021, bringing the price per share...

Vista Gold Corp. (VGZ) Stock Inches Higher After Promising Q1 2021 Financial Reports

Vista Gold Corp. (VGZ) stock prices were up by an incremental 1.82% as of the market closing on May 11th, 2021, bringing the price...

Array Technologies, Inc. (ARRY) Stock Prices Stay Stable Despite Troubling Q1 2021 Financial Reports

Array Technologies, Inc. (ARRY) stock prices were up by a marginal 0.28% as of the market closing on May 11th, 2021, bringing the price...

Lucira Health Inc. (NASDAQ:LHDX) stock rallied today in the current trading session; here’s why

In the current trading session at last check, Lucira Health Inc. (LHDX) shares had surged by 15.32% to the price of $5.87. LHDX's stock...

PaySign, Inc. (PAYS) Stock Down Following Disclosure of Troubling Q1 2021 Financial Reports

PaySign, Inc. (PAYS) stock prices were down 15.0568% early in the trading day on May 12th, 2021, bringing the price per share down to...

Comstock Mining Inc. (NASDAQ:LODE) stock plunged in the current trading session; here’s why

In the current trading session at the last check, Comstock Mining Inc. (LODE) stock had plunged -3.25% to trade at $3.21. LODE stock previously...

Related News

Amarin Corporation plc (NASDAQ: AMRN) stock plunged in the premarket trading session; here’s why

In the premarket trading session, Amarin Corporation plc (AMRN) stock had plunged by -4.56% to $4.4. AMRN stock closed previous session at $4.61 gaining...

Why Second Sight Medical Products, Inc. (EYES) stock is Popping High today?

Second Sight Medical Products, Inc. (EYES) stock announced two-year results of its Orion Study after which the EYES stock price happened to be green...

Luokung Technology Corp. (LKCO) Stock Undergoes Volatility as Appeal Over CCMC Designation is Underway

Luokung Technology Corp. (LKCO) stock prices were down by 6.40% as of the market closing on May 11th, 2021, bringing the price per share...

Vista Gold Corp. (VGZ) Stock Inches Higher After Promising Q1 2021 Financial Reports

Vista Gold Corp. (VGZ) stock prices were up by an incremental 1.82% as of the market closing on May 11th, 2021, bringing the price...

Array Technologies, Inc. (ARRY) Stock Prices Stay Stable Despite Troubling Q1 2021 Financial Reports

Array Technologies, Inc. (ARRY) stock prices were up by a marginal 0.28% as of the market closing on May 11th, 2021, bringing the price...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Insider Watchlist

Important Earnings

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.